Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-05-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 8.2% (raises risk) · Sponsor's track record
• Minimum age: 50 (lowers risk) · Who can join
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Sponsor's past trials: 1272 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 9.6% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 150 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 73.5% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: time ofthe timearteryfailureprior
  Phrases that lowered it: diseasesvisitaspirincopdlong term
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Keywords listed: 25 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia NCT02260622 · started 2014 · scored riskier than 36% of active trials completed
• A Study to Evaluate the Efficacy and Safety of UI022/UI023 NCT07600385 · started 2019 · scored riskier than 24% of active trials completed
• The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM NCT03174522 · started 2017 · scored riskier than 82% of active trials terminated
• Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC) NCT01679990 · started 2012 · scored riskier than 60% of active trials completed
• Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities NCT02217501 · started 2015 · scored riskier than 77% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.